Primecap Management Co. CA Has $1.01 Billion Stake in Elanco Animal Health Incorporated $ELAN

Primecap Management Co. CA trimmed its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 3.5% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 49,958,156 shares of the company’s stock after selling 1,808,658 shares during the period. Primecap Management Co. CA owned 10.05% of Elanco Animal Health worth $1,006,157,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ELAN. Jennison Associates LLC raised its position in shares of Elanco Animal Health by 322.0% in the second quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock valued at $46,192,000 after purchasing an additional 2,468,122 shares during the period. Goldman Sachs Group Inc. grew its stake in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares during the last quarter. Bowen Hanes & Co. Inc. bought a new position in Elanco Animal Health in the 3rd quarter worth $47,626,000. Jupiter Asset Management Ltd. raised its holdings in Elanco Animal Health by 98.8% in the 3rd quarter. Jupiter Asset Management Ltd. now owns 3,716,849 shares of the company’s stock worth $74,857,000 after acquiring an additional 1,846,907 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Elanco Animal Health by 266.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,918,336 shares of the company’s stock worth $38,635,000 after acquiring an additional 1,394,839 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 1.7%

Shares of ELAN stock opened at $26.82 on Thursday. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $27.72. The stock has a market cap of $13.33 billion, a price-to-earnings ratio of -55.87, a P/E/G ratio of 3.92 and a beta of 1.87. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The firm has a fifty day moving average of $24.07 and a 200-day moving average of $21.66.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.14%. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period in the previous year, the business earned $0.14 EPS. The firm’s revenue was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ELAN. Argus raised Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Wednesday, November 19th. Leerink Partners raised their target price on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday. Zacks Research downgraded Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $27.67.

Insider Buying and Selling

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of the business’s stock in a transaction on Friday, December 12th. The stock was bought at an average cost of $21.30 per share, with a total value of $213,000.00. Following the completion of the acquisition, the director owned 131,773 shares in the company, valued at $2,806,764.90. The trade was a 8.21% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jeffrey N. Simmons bought 22,000 shares of Elanco Animal Health stock in a transaction dated Thursday, December 11th. The stock was purchased at an average price of $21.75 per share, for a total transaction of $478,500.00. Following the purchase, the chief executive officer directly owned 167,000 shares in the company, valued at $3,632,250. This represents a 15.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders acquired 43,450 shares of company stock valued at $937,883. 0.89% of the stock is currently owned by corporate insiders.

Trending Headlines about Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q4 beat and upgraded FY‑2026 targets — Elanco reported Q4 revenue of $1.14B and adjusted EPS of $0.13 (above estimates), raised its FY‑2026 innovation revenue target to $1.15B and gave full‑year guidance for ~4%–6% organic growth and higher adjusted EBITDA/adjusted EPS targets. PR Newswire
• Positive Sentiment: Product launches driving innovation revenue — Management says all “Big 6” products are in market with Befrena approved in Q4, supporting the raised innovation revenue target and longer‑term growth thesis. MSN article
• Positive Sentiment: Analyst bullishness — KeyCorp and Leerink raised price targets (to $29 and $30 respectively) and maintained positive ratings, signaling dealer confidence in beat‑and‑raise execution. StreetInsider
• Positive Sentiment: Short interest fell sharply — Short interest dropped ~20.7% in February to ~18.4M shares (≈3.7% of float), lowering potential short‑squeeze risk and reducing downward pressure. (Days‑to‑cover ≈4.0 days).
• Neutral Sentiment: CEO visibility — Jeff Simmons appeared on CNBC with Jim Cramer, raising public visibility for the turnaround narrative; useful for sentiment but not a direct earnings lever. CNBC interview
• Neutral Sentiment: Earnings materials available — Call transcript and slides were published for investors to dig into segment trends and product cadence. Seeking Alpha transcript
• Negative Sentiment: Margin pressure flagged — Some coverage notes margins and cost trends prompted investor concern and caused shares to slip intra‑day despite the beat. That creates risk if GM/EBITDA margins remain under pressure. Investing.com
• Negative Sentiment: Mixed analyst view / limited near‑term upside — Morgan Stanley raised its target to $24 but kept an “equal weight” stance, implying limited upside (their PT sits below current levels), highlighting divergent analyst views on valuation. Benzinga
• Negative Sentiment: Q1 guidance slightly cautious — Q1 EPS guidance of $0.33–$0.36 is roughly in line but slightly below some consensus points, so near‑term beat risk is lower than for FY. (Company guidance details in the PR release above.)

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.